Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy

Journal of Hepatology

Volumn 37, Issue 6, 2002, Pages 824-830

  Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Tsubota, Akihito ^a   Akuta, Norio ^a   Someya, Takashi ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Core promoter; Hepatitis B virus; Lamivudine; Mutant; Polymerase; Precore

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA; CORE PROTEIN; DNA DIRECTED DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; BLOOD; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; MUTATION; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; BASE SEQUENCE; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE INHIBITORS; VIRAL CORE PROTEINS;

EID: 0036893202     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00281-7     Document Type: Article

References (29)

1. Beasley RP, Hwang LW, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981;ii:1129-1133.
2. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B treated with interferon alpha. Gastroenterology 1993;105:1833-1838.
3. Dienstag JL, Perrilo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
4. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
5. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
6. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-748.
7. Honkoop P, Man RA, Niesters HGM, Zondervan PE, Schalm SW. Acure exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
8. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
9. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-1395.
10. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology 1998;27:1711-1716.
11. Liaw YF, Leung NW, Chag TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180.
12. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633.
13. Ling R, Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 1999;80:601-606.
14. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfusion. Hepatology 1999;29:939-945.
15. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, et al. Susceptibility of lamivudine-resistance hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635-1640.
16. Chu C-M, Karayiannis P, Fowler MJF, Monjardino J, Liaw Y-F, Thomas HC. Natural history of chronic hepatitis B virus infection in Taiwan: Studies of hepatitis B virus DNA in serum. Hepatology 1985;5:431-434.
17. Carman WF, Jacyna MR, Hadziyannis P, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 1989;ii:588-591.
18. Lok ASF, Akarca US, Greene S. Mutations in pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal. Proc Natl Acad Sci USA 1994;91:4077-4081.
19. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994;68:1651-1659.
20. Buckword VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-5851.
21. Cho SW, Hahm K-B, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000;32:1163-1169.
22. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-1326.
23. Lau DTY, Khokhar F, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.
24. Lok ASF, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
25. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Waiters KA, Tyrell DLJ, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-1677.
26. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088.
27. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-707.
28. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633.
29. Fu L, Cheng Y-C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC(3TC) resistance. Biochem Pharmacol 1998;55:1567-1572.